Ilaria Puxeddu

Prof. Ilaria Puxeddu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2020 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
DGDaiana Giannini
Daiana Giannini
MAMatteo Antonucci
Matteo Antonucci
FPFiorella Petrelli
Fiorella Petrelli
SBSilvia Bilia
Silvia Bilia
AAAlessia Alunno
Alessia Alunno
IPIlaria Puxeddu
Ilaria Puxeddu
One year in review; Authors: D. Giannini, M. Antonucci, F. Petrelli, S. Bilia, A. Alunno, I. Puxeddu

1 May 2019
Verified
Journal Article
Closed access
CCCristina Croia
Cristina Croia
RBRoberto Bursi
Roberto Bursi
DSDonatella Sutera
Donatella Sutera
FPFiorella Petrelli
Fiorella Petrelli
AAAlessia Alunno
Alessia Alunno
IPIlaria Puxeddu
Ilaria Puxeddu

8 February 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
PIPaola Italiani
Paola Italiani
MMMaria L. Manca
Maria L. Manca
FAFrancesca Angelotti
Francesca Angelotti
DMDaniela Melillo
Daniela Melillo
FPFederico Pratesi
Federico Pratesi
PMPaola Migliorini
Paola Migliorini
Dysregulated production of cytokines has a critical role in systemic lupus. The aim of this work is to identify, by a comprehensive analysis of IL-1 family cytokines and receptors in serum, correlation between cytokines/receptors’ levels and the clinical and serological features of the disease. A full clinical evaluation was performed in 74 patients with systemic lupus erythematosus (SLE). C3, C4, anti-dsDNA and anti-C1q antibodies were measured. Cytokines of the IL-1 family (IL-1α, IL-1β, IL-33, IL-18), soluble receptors (sIL-1R1, sIL-1R2, sIL-1R3, ST2/sIL-1R4) and antagonists (IL-1Ra, IL-18 binding protein (IL-18BP)) were measured in serum by multiarray ELISA. Free IL-18 was calculated as the amount of IL-18 not inhibited by IL-18BP. Data were analysed by non-parametric tests and by multivariate analysis, using partial least squares (PLS) models. Total IL-18, IL-18BP, sIL-1R4 and IL-1Ra levels were higher in SLE vs. controls. Total and free IL-18 and sIL-1R4 were higher in patients with active vs. inactive disease and correlated with ECLAM, anti-C1q and anti-dsDNA antibodies. sIL-1R2 was higher in patients with inactive disease, was negatively correlated with ECLAM and anti-C1q antibodies and was positively correlated with C3 levels. PLS identified sIL-1R4, sIL-1R2 and anti-dsDNA as variables distinguishing patients with active from those with inactive disease; sIL-1R4, IL-18BP and anti-dsDNA identified patients with active nephritis; sIL-1R4, C3, IL-18 and free IL-18 identified patients with haematological involvement. The data support the use of IL-18, sIL-1R2 and sIL-1R4 as biomarkers of disease activity and organ involvement, and suggest that failure in the inhibition of IL-1 activation may be a critical event in the active stages of SLE.

22 March 2022 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
FPFiorella Petrelli
Fiorella Petrelli
FMFrancesco Maria Mariani
Francesco Maria Mariani
AAAlessia Alunno
Alessia Alunno
IPIlaria Puxeddu
Ilaria Puxeddu
One year in review; Authors: F. Petrelli, F.M. Mariani, A. Alunno, I. Puxeddu

21 May 2021 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
DTDavide Testa
Davide Testa
SCSantina Calvacchi
Santina Calvacchi
FPFiorella Petrelli
Fiorella Petrelli
DGDaiana Giannini
Daiana Giannini
SBSilvia Bilia
Silvia Bilia
IPIlaria Puxeddu
Ilaria Puxeddu
One year in review; Authors: D. Testa, S. Calvacchi, F. Petrelli, D. Giannini, S. Bilia, A. Alunno, I. Puxeddu

1 September 2019 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
IPIlaria Puxeddu
Ilaria Puxeddu
FPFiorella Petrelli
Fiorella Petrelli
FAFrancesca Angelotti
Francesca Angelotti
CCCristina Croia
Cristina Croia
PMPaola Migliorini
Paola Migliorini
Chronic urticaria (CU) is a mast cell-driven disease characterized by the development of wheals, angioedema, or both for more than 6 weeks. The two major sub-types are chronic spontaneous urticaria (CSU) and inducible urticaria. In the last decade different pathophysiological mechanisms, potentially responsible for the development of the disease, have been described. It is likely that the activation of mast cells and basophils in CSU can be the results of immune system dysregulation, activation of the inflammatory cascade, and of the extrinsic coagulation pathway. Some of the mediators involved in the pathophysiological mechanisms of CSU have recently been identified as potential biomarkers useful for the diagnosis, follow-up, and management of the disease, even if they are not yet available in clinical practice. Thus, in this review we discuss new insights in the mediators involved in the pathogenesis of CSU, highlighting their potential role as biomarkers in the activity and progression of the disease and response to therapies.